AR
CPRX

Advisory Research’s Catalyst Pharmaceutical CPRX Stock Holding History

Advisory Research’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-70,628
Closed -$1.31M – 366
2022
Q4 		$1.31M Buy
70,628
+22,097
+46% +$340K 0.12% 122
2022
Q3 		$623K Buy
+48,531
New +$575K 0.06% 212

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $18.8B AUM 29.2% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Advisory Research's CPRX Position: Q1 2023 in Review

Advisory Research sold out of Catalyst Pharmaceutical (CPRX) in Q1 2023, closing a stake of 70,628 shares — an estimated $1.31M sold.

Advisory Research first reported a position in CPRX in Q3 2022 and held it in 2 quarters. The position peaked at $1.31M in Q4 2022. 259 funds tracked by Wall St. Rank hold CPRX as of Q1 2023.

  • Advisory Research reported no remaining Catalyst Pharmaceutical position as of Q1 2023 after selling out during the quarter.
  • Advisory Research sold 70,628 Catalyst Pharmaceutical shares in Q1 2023, an estimated $1.31M.
  • Advisory Research first reported a position in Catalyst Pharmaceutical in Q3 2022 and held it in 2 quarters.
  • Advisory Research's Catalyst Pharmaceutical position peaked at $1.31M in Q4 2022.
  • 259 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2023.

Based on Advisory Research's 13F filing for Q1 2023, filed 12 May 2023.